Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.48
+7.2%
$1.15
$0.86
$3.60
$83.59M0.11295,169 shs675,856 shs
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
$10.50
$10.46
$2.00
$10.50
$231.40M-4.81142,261 shsN/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
$0.30
$0.30
$0.18
$5.90
$45.43M1.44486,986 shs732 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.66
+0.2%
$3.78
$3.36
$12.22
$147.37M1.114,494 shs1,367 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+5.34%+10.40%+21.05%+53.20%-56.19%
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
0.00%0.00%0.00%0.00%0.00%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
+1.86%-0.82%-5.90%-8.84%-43.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.8697 of 5 stars
3.54.00.00.01.91.70.6
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.1203 of 5 stars
3.85.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3.00
Buy$6.33327.93% Upside
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00
N/AN/AN/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
0.00
N/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00227.96% Upside

Current Analyst Ratings Breakdown

Latest CMPI, ABOS, GRNA, and MOLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$3.03 per shareN/A
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/A$2.50 per shareN/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
$10.20M4.45N/AN/A$0.32 per share0.94
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M26.15N/AN/A$3.99 per share0.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
-$167.05M-$1.14N/AN/A-1,521.00%-374.26%-122.78%N/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)

Latest CMPI, ABOS, GRNA, and MOLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.54N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/13/2025Q1 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.56-$0.48+$0.08-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/A
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
8.02
8.02
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/A
5.20
5.20
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
0.49
1.21
1.21
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
74.56%
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
24.41%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million54.94 millionOptionable
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
2822.04 million8.24 millionNot Optionable
GreenLight Biosciences Holdings stock logo
GRNA
GreenLight Biosciences
280151.68 million105.72 millionNot Optionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable

Recent News About These Companies

Molecular Partners AG (MOLN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.48 +0.10 (+7.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 +0.03 (+2.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Checkmate Pharmaceuticals stock logo

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

GreenLight Biosciences stock logo

GreenLight Biosciences NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.66 +0.01 (+0.25%)
Closing price 03:46 PM Eastern
Extended Trading
$3.66 +0.00 (+0.03%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.